Literature DB >> 9665666

Antioxidant properties of nicergoline; inhibition of brain auto-oxidation and superoxide production of neutrophils in rats.

M Tanaka1, T Yoshida, K Okamoto, S Hirai.   

Abstract

Oxidative stress has been suggested to adversely influence cerebrovascular disorders and some neurodegenerative disorders. We examined whether nicergoline, an agent widely used for treating cerebrovascular disorders and senile mental impairment, possesses antioxidant activities and some beneficial effect on neutrophils generating free radicals. Although nicergoline did not scavenge superoxide produced from a superoxide-generating system, it significantly inhibited superoxide secretion from stimulated neutrophils. Auto-oxidation of brain homogenate of rats, monitored by formation of thiobarbituric acid-reactive substances, was suppressed by nicergoline in a dose-dependent manner. The oxidation of the homogenate was accelerated by activated neutrophils and was significantly suppressed by nicergoline. These observations suggest that nicergoine is an antioxidant that inhibits not only lipid peroxidation but also free radical generation from neutrophils. These properties of nicergoline should be beneficial in some pathological conditions including cerebrovascular and neurodegenerative disorders in which oxidative stress may have a pathoetiological role.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9665666     DOI: 10.1016/s0304-3940(98)00310-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  Determination of metabolite of nicergoline in human plasma by high-performance liquid chromatography and its application in pharmacokinetic studies.

Authors:  Rong Zheng; Yi-Hong Wu; De-Xi Jiang; Dan Zhang
Journal:  J Pharm Anal       Date:  2012-01-04

Review 2.  Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.

Authors:  Owen Sanders; Lekshmy Rajagopal
Journal:  J Alzheimers Dis Rep       Date:  2020-06-16

3.  A clinical trial of nicergoline to prevent temporary threshold shift.

Authors:  Pana Klamkam; Rongrat Pagcharoenpol; Treewit Treesaranuwattana; Pichayen Silpsrikul; Pariyanan Jaruchinda; Piyalarp Wasuwat; Picha Suwannahitatorn
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-01-25

Review 4.  Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs.

Authors:  Matěj Malík; Pavel Tlustoš
Journal:  Nutrients       Date:  2022-08-17       Impact factor: 6.706

Review 5.  Therapeutic use of nicergoline.

Authors:  Bengt Winblad; Mario Fioravanti; Tomas Dolezal; Inara Logina; Ivan Gospodinov Milanov; Dinu Cristian Popescu; Alina Solomon
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.